Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope.
Based on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.
To date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced.
Company Details
- Employees
- 33
- Founded
- -
- Address
- San Francisco, California 94107, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://switchthera.com/
- HQ
- San Francisco, California
Switch Therapeutics Questions
Switch Therapeutics's website is https://switchthera.com/
Switch Therapeutics's LinkedIn profile is https://www.linkedin.com/company/switch-therapeutics
Switch Therapeutics has
33 employees.
View email and phone details for 33
employees at Switch Therapeutics.
Switch Therapeutics's industry is
Biotechnology Research
Switch Therapeutics's top competitors are
Libra Therapeutics,
Retro Biosciences,
Deciduous Therapeutics,
Judo Bio,
Twist Bioscience,
Aro Biotherapeutics,
Antios Therapeutics,
Dem Biopharma, Inc.,
Capacity Bio,
City Therapeutics.
Switch Therapeutics's categories are Biotechnology Research
Switch Therapeutics's founding year is 2020
